BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses.

First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today provided a corporate update and anticipated milestones for 2021

Walgreens has administered more than 1 million COVID-19 vaccinations across long-term care facilities and other vulnerable populations identified as part of state and jurisdiction distribution plans.

GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Clinigen K.K. (“Clinigen”), headquartered in Tokyo, has received on January 22, 2021, Japan manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg (generic name: idursulfase-beta (recombinant)) as a treatment for mucopolysaccharidosis type II (Hunter syndrome).

Integrated BioPharma, Inc. (OTCQX:INBP) , upgraded to the OTCQX; Best Market from OTCQB; Venture Market as of today. OTC Markets Group Inc. (OTCQX:OTCM) is an operator of financial markets for 11,000 U.S. and global securities. Integrated BioPharma, Inc. begins trading today on OTCQX

Asia Green Biotechnology Corp. (“AGB” or the “Company”) (CSE:ASIA), announced today that, subject to regulatory approval, Mr. Alisdair Leeson, CA, has been appointed as a member of the Board of Directors.

BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ): presents unaudited financial results for second quarter of 2021

Significant improvements have been made to light-responsive eyewear for migraine sufferers.